Rational identification of a novel peptide for targeting nanocarriers to 9L glioma

Journal of Biomedical Materials Research - Part A

Volumn 87, Issue 3, 2008, Pages 728-738

  Agarwal, Abhiruchi ^a   Jaye, David L ^b   Giegerman, Cissy M ^b   Bellamkonda, Ravi V ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

9L glioma; Drug delivery; Liposomal nanocarriers; Peptides; Phage display

Indexed keywords

AMINO ACIDS; BLOOD; CELLS; DRUG DELIVERY; INGOT MOLDS; LIPOSOMES; ORGANIC ACIDS; PEPTIDES; PHOSPHOLIPIDS; PLASMAS; PROTEINS; TUMORS; DAMAGE DETECTION;

9L GLIOMA; AMINO ACID PEPTIDES; CIRCULATION TIMES; COLLATERAL DAMAGES; DOXORUBICIN; DRUG UPTAKES; GLIOSARCOMA; HIGH GRADES; LIPOSOMAL NANOCARRIERS; NANOCARRIERS; NORMAL TISSUES; OLIGO PEPTIDES; PHAGE DISPLAY; PHAGE DISPLAY LIBRARIES; RAT BLOODS;

AMINES;

AMINO ACID; ARGINYLSERYLISOLEUCYLGLUTAMYLTRYPTOPHYLSERYLGLYCYLLEUCYL TRYPTOPHYLGLYCYLPROLYLPROLYLVALYLGLUTAMYLSERYLCYSTEINE; DOXORUBICIN; LIPOSOME; NANOCARRIER; OLIGOPEPTIDE; PEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOMATERIAL; ARGINYLSERYLISOLEUCINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; CIRCULATION TIME; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; GLIOMA; GLIOSARCOMA; IMMUNOCOMPETENCE; NONHUMAN; PHAGE DISPLAY; PLASMA HALF LIFE; PROTEIN ANALYSIS; PROTEIN TARGETING; RAT; TUMOR CELL; TUMOR VOLUME; ANIMAL; FISCHER 344 RAT; MALE; METABOLISM; TUMOR CELL CULTURE; ANIMAL TISSUE; CYTOTOXICITY; DRUG HALF LIFE; DRUG TRANSPORT; HUMAN; HUMAN CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG CARRIERS; GLIOSARCOMA; LIPOSOMES; MALE; NANOSTRUCTURES; PEPTIDES; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 56349112809     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31762     Document Type: Article

References (47)

1. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: A historical- and futuristic-perspective. J Neurooncol 2005;75:253-266.
2. Siegel MJ, Finlay JL, Zacharoulis S. State of the art chemotherapeutic management of pediatric brain tumors. Expert Rev Neurother 2006;6:765-779.
3. Chang SM, Butowski NA, Sneed PK, Garner IV. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus 2006;20:E4
4. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: An update and review of the literature. Acta Neuropathol (Berl) 2006;111:197-212.
5. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88:11460-11464.
6. Zalipsky S, Brandeis E, Newman MS, Woodle MC. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett 1994;353:71-74.
7. Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 1997;14:992-998.
8. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technol Today 1999;11:441-449.
9. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-284
10. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41: 189-207.
11. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y. Passive targeting of doxorubicin with polymer coated liposomes in tumor bearing rats. Biol Pharm Bull 2001;24:795-799.
12. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Polyethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 1995;6:187-194.
13. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92:49-67.
14. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003;9: 6551-6559.
15. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006;16:175-183.
16. McNeeley KM, Annapragada A, Bellamkonda RV. Decreased circulation time offsets increased efficacy of PEGylated nano-carriers targeting folate receptors of glioma. Nanotechnology 2007;18:11.
17. Spear MA, Breakefield XO, Beltzer J, Schuback D, Weissleder R, Pardo FS, Ladner R. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Ther 2001;8:506-511.
18. Samoylova TI, Petrenko VA, Morrison NE, Globa LP, Baker HJ, Cox NR. Phage probes for malignant glial cells. Mol Cancer Ther 2003;2:1129-1137.
19. Ho IA, Lam PY, Hui KM. Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Hum Gene Ther 2004;15:719-732.
20. Schluesener HJ, Xianglin T. Selection of recombinant phages binding to pathological endothelial and tumor cells of rat glioblastoma by in-vivo display. J Neurol Sci 2004;224:77-82.
21. Kolonin MG, Sun J, Do KA, Vidal CI, Ji Y, Baggerly KA, Pasqualini R, Arap W. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006;20:979-981.
22. Li XB, Schluesener HJ, Xu SQ. Molecular addresses of tumors: Selection by in vivo phage display. Arch Immunol Ther Exp (Warsz) 2006;54:177-181.
23. Mazzucchelli L, Burritt JB, Jesaitis AJ, Nusrat A, Liang TW, Gewirtz AT, Schnell FJ, Parkos CA. Cell-specific peptide binding by human neutrophils. Blood 1999;93:1738-1748.
24. Jaye DL, Edens HA, Mazzucchelli L, Parkos CA. Novel G protein-coupled responses in leukocytes elicited by a chemotactic bacteriophage displaying a cell type-selective binding peptide. J Immunol 2001;166:7250-7259.
25. Jaye DL, Nolte FS, Mazzucchelli L, Geigerman C, Akyildiz A, Parkos CA. Use of real-time polymerase chain reaction to identify cell- and tissue-type-selective peptides by phage display. Am J Pathol 2003;162:1419-1429.
26. Jaye DL, Geigerman CM, Fuller RE, Akyildiz A, Parkos CA. Direct fluorochrome labeling of phage display library clones for studying binding specificities: Applications in flow cytometry and fluorescence microscopy. J Immunol Methods 2004; 295:119-127.
27. Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006;114:277-287.
28. Bolotin EM, Cohen R, Bar LK, Emanuel N, Ninio S, Lasic DD, Barenholz Y. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res 1994;4:455-479.
29. Eavarone DA, Yu X, Bellamkonda RV. Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 2000;51:10-14
30. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004;1663:167-177.
31. Nomura K, Hoshino T, Deen DF, Knebel KD. Perturbed cell kinetics of 9L rat brain tumor cells following dianhydrogalactitol. Cancer Treat Rep 1978;62:2055-2061.
32. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim Biophys Acta 1991;1068:133-141.
33. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 1997;118:153-160.
34. Gupta B, Torchilin VP. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother 2007;56:1215-1223.
35. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: Park JW, et al., Anti-HER2 immunoliposomes: Enhanced efficacy due to targeted delivery. Clin. Cancer Res 2002;8:1172-1181. Clin Cancer Res 2002;8:955-956.
36. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-1136.
37. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs 2006;17:1003-1016.
38. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-380.
39. Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 2003;90:509-517.
40. Lee TY, Wu HC, Tseng YL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 2004;64:8002-8008.
41. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006;114:1504-1511.
42. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29 (6 Suppl 16):3-9.
43. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54 (Suppl 4):15-21.
44. Harris JM, Martin NE, Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40: 539-551.
45. Eto Y, Gao JQ, Sekiguchi F, Kurachi S, Katayama K, Maeda M, Kawasaki K, Mizuguchi H, Hayakawa T, Tsutsumi Y, Mayumi T, Nakagawa S. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005;7:604-612.
46. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151:201-215.
47. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Suss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta 2006;1758:1633-1640.